Free Trial
NASDAQ:ICCC

ImmuCell (ICCC) Stock Price, News & Analysis

ImmuCell logo
$6.72 +0.33 (+5.09%)
As of 07/3/2025 01:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About ImmuCell Stock (NASDAQ:ICCC)

Key Stats

Today's Range
$6.21
$6.53
50-Day Range
$4.91
$7.60
52-Week Range
$3.34
$7.60
Volume
1,844 shs
Average Volume
24,968 shs
Market Capitalization
$60.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ImmuCell Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
6th Percentile Overall Score

ICCC MarketRank™: 

ImmuCell scored higher than 6% of companies evaluated by MarketBeat, and ranked 2767th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for ImmuCell.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ImmuCell is -95.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ImmuCell is -95.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ImmuCell has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about ImmuCell's valuation and earnings.
  • Percentage of Shares Shorted

    0.13% of the float of ImmuCell has been sold short.
  • Short Interest Ratio / Days to Cover

    ImmuCell has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ImmuCell has recently increased by 28.07%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    ImmuCell does not currently pay a dividend.

  • Dividend Growth

    ImmuCell does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.13% of the float of ImmuCell has been sold short.
  • Short Interest Ratio / Days to Cover

    ImmuCell has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ImmuCell has recently increased by 28.07%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    ImmuCell has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for ImmuCell this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, ImmuCell insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.60% of the stock of ImmuCell is held by insiders.

  • Percentage Held by Institutions

    Only 13.47% of the stock of ImmuCell is held by institutions.

  • Read more about ImmuCell's insider trading history.
Receive ICCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter.

ICCC Stock News Headlines

ImmuCell Embarks on CEO Succession Planning Process
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

ICCC Stock Analysis - Frequently Asked Questions

ImmuCell's stock was trading at $5.15 at the start of the year. Since then, ICCC shares have increased by 30.4% and is now trading at $6.7150.

ImmuCell Corporation (NASDAQ:ICCC) posted its earnings results on Wednesday, May, 14th. The biotechnology company reported $0.16 EPS for the quarter. The biotechnology company had revenue of $8.07 million for the quarter. ImmuCell had a negative net margin of 1.00% and a negative trailing twelve-month return on equity of 1.02%.
Read the conference call transcript
.

Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Altimmune (ALT), Biocept (BIOC), ImmunoGen (IMGN), Novavax (NVAX) and Pfizer (PFE).

Company Calendar

Last Earnings
5/14/2025
Today
7/04/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ICCC
Employees
70
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.16 million
Pretax Margin
-0.96%

Debt

Sales & Book Value

Annual Sales
$26.49 million
Cash Flow
$0.07 per share
Price / Cash Flow
99.38
Book Value
$3.09 per share
Price / Book
2.17

Miscellaneous

Free Float
8,441,000
Market Cap
$60.70 million
Optionable
Not Optionable
Beta
0.32

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ICCC) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners